Tag Archive for: neurodegeneration

Mission Therapeutics announces publication in Nature Reviews Drug Discovery of article highlighting how neurodegenerative diseases can be tackled by enhancing mitophagy

/in

Review article in high impact journal outlines the evidence that neurodegenerative diseases –including Parkinson’s, Alzheimer’s, ALS and Huntington’s – can be addressed by boosting mitophagy, the quality control system cells use to remove dysfunctional mitochondria Strong evidence has emerged that deficient mitophagy is an underlying cause of neurodegenerative disease Momentum is building, with the first […]

Read more

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

/in

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Read more

Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia

/in

Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion of the single ascending dose stage of its first-in-human trial of VES001 in healthy volunteers. VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as […]

Read more

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

/in

Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to […]

Read more

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

/in

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

Read more